Abstract
Rationale: To evaluate the feasibility of in suite Zr89 labeled radiotracer positron emission tomography-computed tomography (PET/CT)-guided biopsies performed without reinjection. Methods: From 2013-2016, 12 patients (7 males, 5 females; mean age 61 years, range 40-75) with suspected metastatic prostate or breast carcinoma on either imaging or biochemical progression underwent 14 percutaneous biopsies after diagnostic PET/CT using 89Zr labeled radiotracers (mean dose: 180MBq; range: 126-189MBq) targeting prostate specific membrane antigen (PSMA) (n = 7) or human epidermal growth factor receptor 2 (HER2) (n = 5). Biopsies were performed in a PET/CT suite without radiotracer reinjection. Results: Biopsies were performed without complications a mean of 6.2 days (range, 0-13) after injection of radiotracers in bone (n = 7), pleura (n = 3), lymph nodes (n = 2) and liver (n = 2). All biopsies were positive for malignancy on pathology. A concordance between the initial diagnostic imaging findings and biopsies results was observed. The additional radiation (mean dose length product) due to CT procedures was 1581 mGy/cm (379-2686). No complications were reported. Conclusion: Molecular imaging PET/CT-guided biopsies using 89Zr labeled radiotracers are safe and effective without tracer reinjection.
- Copyright © 2017 by the Society of Nuclear Medicine and Molecular Imaging, Inc.